Peter N. Morcos

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 688 citations

Phase 1/2, Neuro-oncology, Dose-finding Portion +9

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris et al. · Journal of Clinical Oncology · 2015 · 578 citations

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana et al. · The Lancet Respiratory Medicine · 2019 · 268 citations

Medicine, Randomised Phase 3, Immunology +9

Correlation of right ventricular ejection fraction and tricuspid annular plane systolic excursion in tetralogy of Fallot by magnetic resonance imaging

Peter N. Morcos, G. Wesley Vick, David J. Sahn et al. · International journal of cardiac imaging · 2008 · 92 citations

Heart Failure, Radiology, Cardiac Mechanic +7